Fibrogen's other approach, a joint effort with Japan's Sankyo , is to screen thousands of small-moleculeproteins on their shelves and those of other firms to see whether one or two will block CTGF from binding with receptors or knock out one of the collagen-producing signals that CTGF sends into a cell nucleus.